Long-term prophylaxis and pharmacokinetic evaluation of intramuscular nano- and microparticle decoquinate in mice infected with P. berghei Sporozoites

10Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Decoquinate nanoparticle and microparticle suspended in an oily vehicle to retard drug release are evaluated for long-term malaria prophylaxis. Pharmacokinetic studies in normal animals and antimalarial efficacy in liver stage malaria mice were conducted at various single intramuscular-decoquinate doses for 2, 4, 6, or 8 weeks prior to infection with P. berghei sporozoites. The liver stage efficacy evaluation was monitored by using an in vivo imaging system. Full causal prophylaxis was shown in mice with a single intramuscular dose at 120 mg/kg of nanoparticle decoquinate (0.43 μm) for 2-3 weeks and with microparticle decoquinate (8.31 μm) injected 8 weeks earlier than inoculation. The time above MIC of 1,375 hr observed with the microparticle formulation provided a 2.2-fold longer drug exposure than with the nanoparticle formulation (624 hr). The prophylactic effect of the microparticle formulation observed in mice was shown to be 3-4 times longer than the nanoparticle decoquinate formulation.

Cite

CITATION STYLE

APA

Li, Q., Xie, L., Caridha, D., Zeng, Q., Zhang, J., Roncal, N., … Hickman, M. (2017). Long-term prophylaxis and pharmacokinetic evaluation of intramuscular nano- and microparticle decoquinate in mice infected with P. berghei Sporozoites. Malaria Research and Treatment, 2017. https://doi.org/10.1155/2017/7508291

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free